<DOC>
	<DOCNO>NCT00036153</DOCNO>
	<brief_summary>The purpose study evaluate efficacy combination tacrolimus + methotrexate compare methotrexate alone treatment sign symptom rheumatoid arthritis 6 month patient partial response methotrexate .</brief_summary>
	<brief_title>Study Assess Efficacy Tacrolimus + Methotrexate Versus Placebo + Methotrexate Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description>This Phase III , 6 month randomize , double-blind , placebo control multi-center study 6 month open-label extension . Patients randomize tacrolimus + methotrexate arm placebo + methotrexate arm ratio 2:1 . Patients complete 6-month double-blind phase eligible enroll open-label phase study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion Criteria Willing discontinue DMARDs , methotrexate Has diagnosis Rheumatoid Arthritis use American College Rheumatology Criteria , least 6 month duration Have receive oral parenteral methotrexate least 3 month Exclusion Criteria Has receive tacrolimus indication Has moderate severe liver disease Has know history HIV infection Has serum creatinine outside normal range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Tacrolimus , PrografÂ® , FK506</keyword>
</DOC>